Financière de Tubize S.A.
TUB
株式のランク
#2220
Financière de Tubize SA, headquartered in Brussels, Belgium, operates as a... Financière de Tubize SA, headquartered in Brussels, Belgium, operates as a global biopharmaceutical firm, primarily through its investment in UCB. The company is dedicated to discovering and advancing innovative medicines and solutions focused on neurological and immunological disorders. Its current commercial offerings include Cimzia, an established treatment for a range of inflammatory conditions such as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis. For partial-onset seizures in epilepsy, it provides Briviact, Vimpat, and Keppra, alongside Nayzilam, a nasal spray. Neupro addresses Parkinson's disease and restless legs syndrome. Additionally, the portfolio features Evenity, an injectable therapy for osteoporosis, and Bimzelx, used to manage moderate to severe plaque psoriasis. The company's development pipeline highlights several promising candidates: Staccato, aimed at stereotypical prolonged seizures; Bepranemab for Alzheimer's disease; and UCB0599 for Parkinson's disease. Other therapies under investigation include bimekizumab, which targets psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis; rozanolixizumab, for conditions like myasthenia gravis, immune thrombocytopenia, myelin oligodendrocyte glycoprotein antibody disease, and autoimmune encephalitis; and dapirolizumab pegol, intended for systemic lupus erythematosus.
株価
$203.04
時価総額
$9.04B
変化（1日）
-7.47%
変化（1年）
-25.36%
国
BE
取引 Financière de Tubize S.A. (TUB)
カテゴリー
Healthcare
Financière de Tubize S.A.（TUB）のP/E比率
October 2026 時点のP/E比率 TTM 78.47
Financière de Tubize S.A. の最新の財務報告および株価によると、現在の P/E (TTM) は 78.47 です。2023 年末時点での P/E は 36.21 でした。
Financière de Tubize S.A. の P/E 比率の履歴（2003 〜 2026）
各年末のP/E比率
| 年 | P/E比率 | 変化 |
|---|---|---|
| 2026 (TTM) | 78.47 | 11.70% |
| 2024 | 70.25 | 94.03% |
| 2023 | 36.21 | -2.15% |
| 2022 | 37.00 | -23.04% |
| 2021 | 48.08 | 240.67% |
| 2020 | 14.11 | 41.49% |
| 2019 | 9.97 | 5.27% |
| 2018 | 9.48 | -7.41% |
| 2017 | 10.23 | -29.79% |
| 2016 | 14.57 | 2.19% |
| 2015 | 14.26 | -63.12% |
| 2014 | 38.67 | 13.57% |
| 2013 | 34.05 | 84.11% |
| 2012 | 18.49 | 10.41% |
| 2011 | 16.75 | -64.32% |
| 2010 | 46.94 | 607.22% |
| 2009 | 6.64 | -101.03% |
| 2008 | -644.73 | -1,915.08% |
| 2007 | 35.52 | 605.75% |
| 2006 | 5.03 | -16.30% |
| 2005 | 6.01 | -50.37% |
| 2004 | 12.12 | 82.43% |
| 2003 | 6.64 | 0.00% |
類似企業や競合他社のP/E比率
| 企業 | P/E比率 | P/E比率の差 | 国 |
|---|---|---|---|
| 28.78 | -63.32% |
US
|
|
| -28.36 | -136.14% |
US
|
|
| -24.57 | -131.31% |
AU
|
|
| 30.33 | -61.35% |
NL
|
|
| - | - |
CH
|
P/E比率の読み方
株価収益率（P/E Ratio）は、企業の株価と1株あたり利益の関係を示します。
低いが正のP/Eは、現在の評価額に対して高い利益を上げている企業を示し、割安と見なされる可能性があります。高い負の（0に近い）P/Eは、損失が大きいことを示します。
P/Eが30を超えるか、負である企業は一般に「成長株」と見なされ、投資家は将来的な成長または黒字化を期待しています。
10未満の正のP/Eを持つ企業は一般に「割安株」と見なされ、既に収益性が高いが成長の余地は小さいと見なされます。